The FDA approved an all-oral combination regimen for newly diagnosed acute myeloid leukemia on May 13. Taiho Pharmaceutical's Inqovi (decitabine plus cedazuridine) combined with venetoclax is now indicated for adults seventy-five and older, or those with comorbidities that preclude intensive induction chemotherapy. [1] It is the first all-oral combination treatment regimen for this AML population, offering an alternative to parenteral hypomethylating-agent infusions that have required frequent clinic visits.
The approval is supported by ASCERTAIN-V (ASTX727-07), a Phase 2b single-arm trial in 101 adult patients newly diagnosed with AML who were ineligible for intensive induction. The complete remission rate was 41.6% (95% CI: 31.9, 51.8) at FDA-set thresholds; median time to CR was two months. The median duration of CR was not reached at the time of analysis (range: 0.5 to 16.3 months). Median overall survival in earlier reporting was 15.5 months. Adverse events grade 3 or higher occurred in 98% of patients — most commonly febrile neutropenia (49.5%), anemia (38.6%), and neutropenia (35.6%) — consistent with the established safety profile of each agent individually. [2]
The clinical news reaches the press release. The hospital-services consequence does not. About 22,720 Americans will be diagnosed with AML in 2026; more than half are ineligible for intensive induction. [1] That population has typically required regular infusion-center visits for parenteral hypomethylating agents plus oral venetoclax — roughly five clinic visits per month, a heavy burden for older patients in rural geographies.
The new regimen is one Inqovi tablet daily on days one through five of each twenty-eight-day cycle, plus oral venetoclax daily, at home. Less infusion-suite occupancy, fewer chair-hours, fewer travel days. The trade-off is tighter adherence monitoring without the visit cadence that previously ensured it. Inqovi was approved in July 2020 for myelodysplastic syndromes; the new AML indication came through Project Orbis with Health Canada as partner. [1] Taiho Oncology CEO Peter Melnyk called it "a significant milestone." It is also a quiet redrawing of how older AML patients in rural America will be treated.
-- NORA WHITFIELD, Chicago